A narrative review of ERBB2 in non-small cell lung carcinoma
M Sharma, A Dewan, H Diwan… - Cancer Research …, 2022 - journals.lww.com
The plethora of biomarkers and the availability of targeted treatment have revolutionized the
therapeutic profile of non-small cell lung cancer (NSCLC). Erythroblastic oncogene B …
therapeutic profile of non-small cell lung cancer (NSCLC). Erythroblastic oncogene B …
[HTML][HTML] Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line …
B Levy, F Barlesi, L Paz-Ares, J Bennouna, M Erman… - Lung Cancer, 2022 - Elsevier
Introduction Afatinib and pembrolizumab have separately shown survival benefit in patients
with squamous cell carcinoma (SqCC) of the lung, and there is biological rationale for …
with squamous cell carcinoma (SqCC) of the lung, and there is biological rationale for …
[HTML][HTML] Squamous cell lung cancer: genomic evolution and personalized therapy
AF Cardona, L Ricaurte… - salud pública de …, 2020 - SciELO Public Health
Objective: To review the state-of-the-art in relation to the current information on squamous
cell lung cancer (SCLC). We describe the genetic anomalies reported, their effect, and finally …
cell lung cancer (SCLC). We describe the genetic anomalies reported, their effect, and finally …
In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial
A Hamada, K Suda, T Koga, T Fujino, M Nishino… - Lung Cancer, 2021 - Elsevier
Abstract Objectives The LUX-Lung 8 randomized trial (LL8) demonstrated a prolonged
progression-free survival (PFS) in patients with metastatic squamous cell carcinoma (SCC) …
progression-free survival (PFS) in patients with metastatic squamous cell carcinoma (SCC) …
[PDF][PDF] 肺鳞状细胞癌靶向治疗研究进展
刘传， 李琦 - 肿瘤, 2024 - tumorsci.org
肺鳞状细胞癌是肺癌的主要组织学类型之一. 与肺腺癌不同, 肺鳞状细胞癌患者从靶向治疗中的
获益有限. 虽然免疫治疗显著改善了肺鳞状细胞癌患者的预后, 但是相对较低的有效率和相关 …
获益有限. 虽然免疫治疗显著改善了肺鳞状细胞癌患者的预后, 但是相对较低的有效率和相关 …
Actualización de las recomendaciones para la determinación de biomarcadores predictivos en el carcinoma de pulmón de célula no pequeña avanzado. Consenso …
F López-Ríos, L Paz-Ares, J Sanz, D Isla… - Revista Española de …, 2020 - Elsevier
En el año 2011 se inició un proyecto conjunto entre la Sociedad Española de Oncología
Médica (SEOM) y la Sociedad Española de Anatomía Patológica (SEAP) para establecer …
Médica (SEOM) y la Sociedad Española de Anatomía Patológica (SEAP) para establecer …
The role of miRNA-571 and miRNA-559 in lung cancer by affecting the expression of genes associated with the ErbB signaling pathway
Background Abnormal expression and activity of the ErbB pathway has been revealed in
many cancers, such as lung cancer. The inappropriate activity of EGFR, MAPK1 and PAK2 …
many cancers, such as lung cancer. The inappropriate activity of EGFR, MAPK1 and PAK2 …
Pharmacokinetics of Afatinib after Intravenous and Oral Administrations in Rats Using Validated UPLC MS/MS Assay
AS Almurshedi, MA Radwan… - Journal of …, 2024 - academic.oup.com
Afatinib is designated as the first-line management therapy for patients with advanced non-
small cell lung cancer, and metastatic head and neck cancer. LC coupled to MS/MS can be …
small cell lung cancer, and metastatic head and neck cancer. LC coupled to MS/MS can be …
PD-L1 Protein Expression and Gene Amplification Correlate with the Clinicopathological Characteristics and Prognosis of Lung Squamous Cell Carcinoma
Z Chen, N Zhao, Q Wang, Y Xi, X Tian… - Cancer Management …, 2021 - Taylor & Francis
Purpose To investigate PD-L1 protein expression and gene amplification in lung squamous
cell carcinoma (LUSC) and analyse their correlation with the clinicopathological …
cell carcinoma (LUSC) and analyse their correlation with the clinicopathological …